Zhitong Finance App News, Sihuan Pharmaceutical (00460) announced that recently, the injectable polycaprolactone microsphere facial filler (PCL) and injectable sodium hyaluronate complex solution (FL) (kinetic energy) independently developed and produced by the group's subsidiary, have been approved for listing in the Hong Kong Special Administrative Region of China. The approved specifications for injectable polycaprolactone microsphere facial fillers include 0.5mL/stick, 1.0mL/ stick; the approved specifications for the injectable sodium hyaluronate compound solution include 0.5mL/stick, 1.0mL/stick, 1.5mL/stick, 2.0mL/stick, 2.5mL/stick, 3.0mL/stick, 5mL/box (containing 2 2.5mL/stick).
According to the announcement, expanding the international market is one of the company's important strategies for medical and aesthetic business, and this year is a year of acceleration in overseas expansion. PCL is a regenerative filler product, and kinetin is a skin care product. They are all mainstream categories in the field of light medicine and beauty, and have had a good sales and market response after being launched in mainland China. This time, the two self-developed products were approved for listing in Hong Kong, which not only expanded the market space for the two products, but also marked a breakthrough in the registration of the Group's medical and aesthetic products in Hong Kong, laying a solid foundation for the Group to deeply cultivate the Hong Kong market and radiate the Asia-Pacific region, and help the Group move towards the long-term development goal of an international medical and aesthetic enterprise. At the same time, this approval also verifies that the R&D, production and quality management system of the Group's medical and aesthetic products meets the regulatory requirements of the Hong Kong region, accumulates valuable practical experience in carrying out global multi-regional registration and certification for the Group's subsequent self-developed medical and aesthetic products, and continues to consolidate the global development base of the medical and aesthetic sector.